

Amendments to the Claims:

The following Listing of Claims replaces all prior versions and listing of the claims in the present application.

Listing of Claims:

1 (Original): Method for prevention of capsular opacification, comprising:

- a) creating an opening in a lens capsule of an eye;
- b) removing the natural lens from the lens capsule;
- c) inserting a capsule filling implant into the lens capsule; and
- d) injecting a composition into the space between the inserted implant and the

lens capsule;

in which method the composition injected in step d) comprises at least one agent capable of inhibiting at least one of the following:

- proliferation of lens epithelial cells;
- migration of lens epithelial cells; and
- production of extra-cellular matrix by lens epithelial cells.

2 (Original): Method according to claim 1, in which step d) is performed in such a way that the composition injected is applied to the germinative zones of epithelial cells, and in such a way that the central parts of the anterior and posterior surfaces of the lens capsule are kept essentially free from the composition.

3 (Original): Method according to claim 1, in which step d) is performed in such a way that the composition injected is applied to the whole of the inside of the lens capsule.

4 (Currently Amended): Method according to claim 1 ~~any one of the preceding claims~~, in which the injection in step d) is performed using an instrument having a hydrophobic outer surface.

5 (Original): Method according to claim 4, in which said instrument is a steel cannula with a hydrophobic coating.

6 (Original): Method according to claim 4, in which said instrument is made from a hydrophobic material.

7 (Currently Amended) Method according to claim 1 ~~any one of the preceding claims~~, in which the size of the opening created in step a) is below 3 mm.

8 (Original): Method according to claim 7, in which the size of the opening created in step a) is from 0.8 to 1.5 mm.

9 (Currently Amended): Method according to claim 1 ~~any one of the preceding claims~~, which further comprises sealing the opening in the lens capsule.

10 (Original): Method according to claim 9, in which said sealing is performed through insertion of a sealing device in the opening before step d), which sealing device permits entry into, and withdrawal from, the lens capsule of instruments for manipulation and/or injection.

11 (Currently Amended): Method according to claim 1 ~~any one of the preceding~~
~~claims~~, in which the capsule filling implant is an artificial lens.

12 (Currently Amended): Method according to claim 11, in which the artificial lens
is a capsule filling lens, ~~such as selected from hydrogel lenses, preformed lenses that are~~
~~rolled into a shape like a cigar, and lenses that are made from lens material injected into the~~
~~lens capsule and then cured by heat or light.~~

13 (Currently Amended): Method according to claim 1 ~~any one of the preceding~~
~~claims~~, in which the capsule filling implant comprises an injectable material, which is
capable of undergoing cross-linking to form a lens implant following injection thereof into
the lens capsule.

14 (Currently Amended): Method according to claim 1 ~~any one of the preceding~~
~~claims~~, in which the at least one agent is present in a physiologically acceptable solution.

15 (Currently Amended): Method according to claim 1 ~~any one of the preceding~~
~~claims~~, in which the at least one agent is present in a physiologically isotonic solution.

16 (Currently Amended): Method according to claim 1 ~~any one of the preceding~~
~~claims~~, in which the at least one agent is present in a hypotonic solution.

17 (Currently Amended): Method according to claim 1 ~~any one of the preceding~~
~~claims~~, in which the at least one agent is present in a hypertonic solution.

18 (Currently Amended): Method according to claim 1 ~~any one of the preceding claims~~, in which the composition comprises a cytotoxic agent.

19 (Currently Amended): Method according to claim 18, in which the cytotoxic agent is selected ~~chosen~~ from the group consisting of saporin, ricin, methotrexate, 5-fluorouracil, daunomycin, doxorubicin, mitoxanthrone, vinca alkaloids, vinblastine, colchicine, cytochasins, monensin, mitomycin and ouabain.

20 (Currently Amended): Method according to claim 1 ~~any one of the preceding claims~~, in which the composition comprises a nucleic acid molecule comprising a gene encoding a protein capable of inducing the death of lens epithelial cells, the gene being subject to transcriptional control specific to said cells.

21 (Currently Amended): Method according to claim 20, in which the gene encoding a protein capable of inducing the death of lens epithelial cells is selected ~~chosen~~ from the group consisting of genes encoding a protein which induces cell death by necrosis and genes encoding a protein which is toxic to lens epithelial cells.

22 (Original): Method according to claim 21, in which the gene encoding a protein capable of inducing the death of lens epithelial cells is a gene encoding a protein which induces apoptosis, or a gene involved in the process of apoptosis.

23 (Currently Amended): Method according to claim 20 ~~any one of claims 20-22~~, in which said gene encoding a protein capable of inducing the death of lens epithelial cells is

selected ~~chosen~~ from the group consisting of genes encoding p53, BAX, FLICE, TRAIL and TRAIL-R.

24 (Currently Amended): Method according to claim 20 ~~any one of claims 20-23~~, in which the gene encoding a protein capable of inducing the death of lens epithelial cells is provided within a vector.

25 (Original): Method according to claim 24, in which said vector is of the adenovirus type.

26 (Currently Amended): Method according to claim 1 ~~any one of the preceding claims~~, in which the composition comprises at least one basement membrane binding agent, which is conjugated to at least one cytotoxic agent.

27 (Currently Amended): Method according to claim 26, in which the at least one cytotoxic agent is selected ~~chosen~~ from the group consisting of ribosomal inhibitory proteins, antimitotic drugs and ionophores.

28 (Original): Method according to claim 27, in which the at least one cytotoxic agent is a ribosomal inhibitory protein.

29 (Currently Amended): Method according to claim 26 ~~any one of claims 26-28~~, in which the at least one basement membrane binding agent is selected ~~chosen~~ from the group consisting of poly-L-lysine, poly-D-lysine, fibronectin, laminin, type I, II, III and IV collagen, thrombospondin, vitronectin, polyarginine and platelet factor IV.

30 (Currently Amended): Method according to claim 29, in which the at least one basement membrane binding agent is ~~chosen from~~ poly-L-lysine or ~~and~~ poly-D-lysine.

31 (Currently Amended): Method according to claim 1 ~~any one of the preceding~~ ~~claims~~, in which the composition comprises a surfactant.

32 (Currently Amended): Method according to claim 1 ~~any one of the preceding~~ ~~claims~~, in which the composition comprises a hypotonic solution.

33 (Currently Amended): Method according to claim 1 ~~any one of the preceding~~ ~~claims~~, in which the composition comprises a hypertonic solution.

34 (Currently Amended): Method according to claim 1 ~~any one of the preceding~~ ~~claims~~, in which the composition comprises a divalent cation chelator.

35 (Currently Amended): Method according to claim 1 ~~any one of the preceding~~ ~~claims~~, in which the composition comprises an arginine-glycine-asparagine (RGID) peptide analog.

36 (Currently Amended): Method according to claim 1 ~~any one of the preceding~~ ~~claims~~, in which the composition comprises an antibody directed against cell attachment receptors.

37 (New): Method according to claim 12, wherein the capsule filling lens is selected from the group consisting of hydrogel lenses, preformed lenses that are rolled into a shape like a cigar, and lenses that are made from lens material injected into the lens capsule and then cured by heat or light.

38 (New): Method according to claim 21, in which said gene encoding a protein capable of inducing the death of lens epithelial cells is selected from the group consisting of genes encoding p53, BAX, FLICE, TRAIL and TRAIL-R.

39 (New): Method according to claim 22, in which said gene encoding a protein capable of inducing the death of lens epithelial cells is selected from the group consisting of genes encoding p53, BAX, FLICE, TRAIL and TRAIL-R.

40 (New): Method according to claim 21, in which the gene encoding a protein capable of inducing the death of lens epithelial cells is provided within a vector.

41 (New): Method according to claim 22, in which the gene encoding a protein capable of inducing the death of lens epithelial cells is provided within a vector.

42 (New): Method according to claim 27, in which the at least one basement membrane binding agent is selected from the group consisting of poly-L-lysine, poly-D-lysine, fibronectin, laminin, type I, II, III and IV collagen, thrombospondin, vitronectin, polyarginine and platelet factor IV.

43 (New): Method according to claim 28, in which the at least one basement membrane binding agent is selected from the group consisting of poly-L-lysine, poly-D-lysine, fibronectin, laminin, type I, II, III and IV collagen, thrombospondin, vitronectin, polyarginine and platelet factor IV.